GlycoMimetics Overview
- Year Founded
-
2003
- Status
-
Acquired/Merged
- Employees
-
26
- Latest Deal Type
-
M&A
GlycoMimetics General Information
Description
GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.
Contact Information
Website
www.glycomimetics.comCorporate Office
- 9708 Medical Center Drive
- Rockville, MD 20850
- United States
Corporate Office
- 9708 Medical Center Drive
- Rockville, MD 20850
- United States
GlycoMimetics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 16-Jun-2025 | Completed | Generating Revenue | |||
| 6. 2PO | 02-Jun-2016 | Completed | Generating Revenue | |||
| 5. IPO | 10-Jan-2014 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC (Series A1) | 27-Oct-2010 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC | 02-Nov-2009 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series B) | 23-Jun-2006 | $15.5M | $24.9M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 06-Sep-2004 | $9.4M | $9.4M | Completed | Product Development |
GlycoMimetics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A1 |
GlycoMimetics Comparisons
Industry
Financing
Details
GlycoMimetics Competitors (64)
One of GlycoMimetics’s 64 competitors is Dicerna Pharmaceuticals, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Galectin Therapeutics | Corporation | Norcross, GA | ||||
| Damora Therapeutics ( Drug Discovery) | Formerly VC-backed | Waltham, MA | ||||
| Liminal Biosciences | Private Equity-Backed | Belleville, Canada | ||||
| Idorsia Pharmaceuticals | Corporation | Allschwil, Switzerland |
GlycoMimetics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
GlycoMimetics Patents
GlycoMimetics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20060081391-A1 | Shield used in wall surface finishing process and method | Inactive | 18-Oct-2004 |
GlycoMimetics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
GlycoMimetics Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Anthem Capital Management | Venture Capital | Minority | ||
| Maryland Department of Commerce | Limited Partner | Minority | ||
| New Enterprise Associates | Venture Capital | Minority | ||
| Novartis Venture Fund | Corporate Venture Capital | Minority | ||
| PTV Healthcare Capital | Venture Capital | Minority |
GlycoMimetics Acquisitions (1)
GlycoMimetics’s most recent deal was a Reverse Merger with Crescent Biopharma. The deal was made on 16-Jun-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Crescent Biopharma | 16-Jun-2025 | Reverse Merger | Biotechnology |
GlycoMimetics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
22.96 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
GlycoMimetics FAQs
-
When was GlycoMimetics founded?
GlycoMimetics was founded in 2003.
-
Where is GlycoMimetics headquartered?
GlycoMimetics is headquartered in Rockville, MD.
-
What is the size of GlycoMimetics?
GlycoMimetics has 26 total employees.
-
What industry is GlycoMimetics in?
GlycoMimetics’s primary industry is Drug Discovery.
-
Is GlycoMimetics a private or public company?
GlycoMimetics is a Private company.
-
What is GlycoMimetics’s current revenue?
The current revenue for GlycoMimetics is .
-
How much funding has GlycoMimetics raised over time?
GlycoMimetics has raised $171M.
-
Who are GlycoMimetics’s investors?
Anthem Capital Management, Maryland Department of Commerce, New Enterprise Associates, Novartis Venture Fund, and PTV Healthcare Capital are 5 of 8 investors who have invested in GlycoMimetics.
-
Who are GlycoMimetics’s competitors?
Dicerna Pharmaceuticals, Galectin Therapeutics, Damora Therapeutics ( Drug Discovery), Liminal Biosciences, and Idorsia Pharmaceuticals are some of the 64 competitors of GlycoMimetics.
-
When was GlycoMimetics acquired?
GlycoMimetics was acquired on 16-Jun-2025.
-
Who acquired GlycoMimetics?
GlycoMimetics was acquired by Crescent Biopharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
